Floatz logo

Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tcm-Enriched T Cells

Recurrent Adult Diffuse Mixed Cell Lymphoma

City of Hope Medical CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Recurrent Adult Diffuse Mixed Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Case Comprehensive Cancer Center
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BBB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 3BBB
Monomethyl Fumarate
University of Medicine and Dentistry of New Jersey
Phase 2BBB

View all 50 →

Same molecule, other indications

Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tcm-Enriched T Cells is also rated in:

primary cutaneous B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
grade III lymphomatoid granulomatosisDormant
CC
Indicative ·
43 / 100
View asset →
intraocular lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →